United States Biotechnology & Medical Research

Y-mAbs Therapeutics, Inc (YMAB)

Track

Ticker: YMAB Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Y-mAbs Therapeutics, Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Sale 7 Mar 2025
Value US$3,569,779.88 | Price 145.15 | Shares 70,255 (-2.4%)
Proposed sale 7 Mar 2025
Value US$2,011,550.79 | Price 334.48 | Shares 16,565
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-03-11 2025-03-07 S Sale
3.1
Gad Thomas

CHIEF BUSINESS OFFICER

Executive Director
70,255 -2.4%
145.15
US$3,569,780 		70,255 -2.4% 145.15 US$3,569,780
2025-03-11 2025-03-07 S Sale
3.0
Rossi Michael J

PRESIDENT & CEO

Executive Director
53,860 -44.3%
430.51
US$2,094,150 		53,860 -44.3% 430.51 US$2,094,150
2025-03-07 2025-03-07 PrS Proposed sale
1.9
Rajah Vignesh

Officer

Officer
77,211
122.82
US$4,782,607 		77,211 122.82 US$4,782,607
2025-03-07 2025-03-07 PrS Proposed sale
3.2
Smith Susan Laura

Officer

Officer
5,528
5.26
US$29,100 		5,528 5.26 US$29,100
2025-03-07 2025-03-07 PrS Proposed sale
3.1
Gad Thomas

Officer; Director

Executive Director
10,810
5.23
US$56,547 		10,810 5.23 US$56,547
2024-09-17 2024-09-16 S Sale
3.1
Gad Thomas

CHIEF BUSINESS OFFICER

Executive Director
30,000 -30.7%
12.97
US$389,100 		30,000 -30.7% 12.97 US$389,100
2024-09-17 2024-09-13 S Sale
3.1
Gad Thomas

CHIEF BUSINESS OFFICER

Executive Director
65,000 -40.0%
13.47
US$875,550 		65,000 -40.0% 13.47 US$875,550
2024-09-13 2024-09-13 PrS Proposed sale
3.1
Thomas Gad

Officer

Officer
100,000
13.74
US$1,374,000 		100,000 13.74 US$1,374,000
2024-09-03 2024-09-03 PrS Proposed sale
1.2
Ber Gerard

Director

Non-Executive Director
13,950
13.83
US$192,928 		13,950 13.83 US$192,928
2024-08-30 2024-08-28 S Sale
3.2
Lund-Hansen Torben

SVP & CHIEF TECHNICAL OFFICER

Officer
50,000 -58.4%
15.37
US$768,500 		50,000 -58.4% 15.37 US$768,500
2024-08-28 2024-08-28 PrS Proposed sale
3.2
Lund-Hansen Torben

Officer

Officer
50,000
15.37
US$768,432 		50,000 15.37 US$768,432
2024-08-27 2024-08-26 S Sale
3.2
Wilms Joris

SVP & CHIEF OPERATING OFFICER

Officer
5,000 -14.0%
14.69
US$73,450 		5,000 -14.0% 14.69 US$73,450
2024-08-26 2024-08-26 PrS Proposed sale
3.2
Wilms Joris

Officer

Officer
5,000
14.69
US$73,450 		5,000 14.69 US$73,450
2024-06-11 2024-06-11 S Sale
3.1
Gad Thomas

CHIEF BUSINESS OFFICER

Executive Director
35,000 -17.7%
12.00
US$420,000 		35,000 -17.7% 12.00 US$420,000
2024-06-11 2024-06-10 S Sale
3.1
Gad Thomas

CHIEF BUSINESS OFFICER

Executive Director
35,000 -15.0%
12.03
US$421,050 		35,000 -15.0% 12.03 US$421,050
2024-06-11 2024-06-10 S Sale
1.2
Ber Gerard
Non-Executive Director
722 -31.0%
12.00
US$8,664 		722 -31.0% 12.00 US$8,664
2024-06-10 2024-06-10 PrS Proposed sale
3.1
Thomas Gad

Officer

Officer
70,000
11.98
US$838,600 		70,000 11.98 US$838,600
2024-06-10 2024-06-10 PrS Proposed sale
1.2
Ber Gerard

Director

Non-Executive Director
722
12.00
US$8,665 		722 12.00 US$8,665
2024-05-31 2024-05-31 S Sale
1.5
Kruse Bo

EVP, CFO, SECRY & TREAS.

Officer
31,371 -12.9%
12.07
US$378,648 		31,371 -12.9% 12.07 US$378,648
2024-05-31 2024-05-30 S Sale
1.5
Kruse Bo

EVP, CFO, SECRY & TREAS.

Officer
28,629 -12.0%
12.03
US$344,407 		28,629 -12.0% 12.03 US$344,407
2024-05-30 2024-05-30 PrS Proposed sale
1.5
Kruse Bo

Officer

Officer
60,000
12.03
US$721,960 		60,000 12.03 US$721,960
2024-05-23 2024-05-23 S Sale
3.1
Gad Thomas

CHIEF BUSINESS OFFICER

Executive Director
7,351 -3.1%
13.00
US$95,563 		7,351 -3.1% 13.00 US$95,563
2024-05-23 2024-05-21 S Sale
3.1
Gad Thomas

CHIEF BUSINESS OFFICER

Executive Director
25,000 -9.4%
12.00
US$300,000 		25,000 -9.4% 12.00 US$300,000
2024-05-21 2024-05-21 PrS Proposed sale
3.1
Thomas Gad

Officer

Officer
100,000
11.93
US$1,193,000 		100,000 11.93 US$1,193,000
2024-03-07 2024-03-05 S Sale
3.2
Smith Susan Laura

SVP & CHIEF COMMERCIAL OFFICER

Officer
1,682 -4.7%
16.55
US$27,837 		1,682 -4.7% 16.55 US$27,837
2024-03-07 2024-03-05 S Sale
3.1
Gad Thomas

CHIEF BUSINESS OFFICER

Executive Director
3,900 -2.4%
16.44
US$64,116 		3,900 -2.4% 16.44 US$64,116
2024-03-07 2024-03-05 S Sale
1.9
Rajah Vignesh

SVP & CHIEF MEDICAL OFFICER

Officer
1,711 -4.8%
16.53
US$28,283 		1,711 -4.8% 16.53 US$28,283
2024-03-06 2024-03-05 PrS Proposed sale
3.2
Smith Susan Laura

Officer

Officer
1,682
16.55
US$27,837 		1,682 16.55 US$27,837
2024-03-06 2024-03-05 PrS Proposed sale
1.9
Rajah Vignesh

Officer

Officer
1,711
16.53
US$28,279 		1,711 16.53 US$28,279
2024-03-05 2024-03-05 PrS Proposed sale
3.1
Gad Thomas

Officer; Director

Executive Director
3,900
16.44
US$64,123 		3,900 16.44 US$64,123
2023-12-15 2023-12-15 S Sale
3.1
Gad Thomas

Chief Business Officer

Executive Director
50,000 -15.9%
6.61
US$330,500 		50,000 -15.9% 6.61 US$330,500
2023-12-15 2023-12-14 S Sale
3.1
Gad Thomas

Chief Business Officer

Executive Director
50,000 -13.7%
6.83
US$341,500 		50,000 -13.7% 6.83 US$341,500
2023-12-15 2023-12-13 S Sale
3.1
Gad Thomas

Chief Business Officer

Executive Director
50,000 -12.0%
6.58
US$329,000 		50,000 -12.0% 6.58 US$329,000
2023-12-13 2023-12-13 PrS Proposed sale
3.1
Gad Enterprises LLC (Thomas Gad)

Officer

Officer
150,000
6.77
US$1,015,500 		150,000 6.77 US$1,015,500
2023-12-12 2023-12-11 B Purchase
3.5
Wedell-Wedellsborg Johan
Non-Executive Director
6,455 +0.1%
6.85
US$44,232 		6,455 +0.1% 6.85 US$44,232
2023-12-12 2023-12-11 B Purchase
3.8
WG Biotech ApS
Non-Executive Director
6,455 +0.1%
6.85
US$44,232 		6,455 +0.1% 6.85 US$44,232
2023-12-11 2023-12-11 B Purchase
3.5
Wedell-Wedellsborg Johan
Non-Executive Director
102,863 +2.3%
7.01
US$720,843 		102,863 +2.3% 7.01 US$720,843
2023-12-11 2023-12-11 B Purchase
3.8
WG Biotech ApS
Non-Executive Director
102,863 +2.3%
7.01
US$720,843 		102,863 +2.3% 7.01 US$720,843
2023-12-11 2023-12-08 B Purchase
3.5
Wedell-Wedellsborg Johan
Non-Executive Director
18,503 +0.4%
6.99
US$129,379 		18,503 +0.4% 6.99 US$129,379
2023-12-11 2023-12-08 B Purchase
3.8
WG Biotech ApS
Non-Executive Director
18,503 +0.4%
6.99
US$129,379 		18,503 +0.4% 6.99 US$129,379
2023-12-11 2023-12-07 B Purchase
3.5
Wedell-Wedellsborg Johan
Non-Executive Director
6,183 +0.1%
6.50
US$40,190 		6,183 +0.1% 6.50 US$40,190
2023-12-11 2023-12-07 B Purchase
3.8
WG Biotech ApS
Non-Executive Director
6,183 +0.1%
6.50
US$40,190 		6,183 +0.1% 6.50 US$40,190
2023-12-01 2023-11-29 B Purchase
3.8
WG Biotech ApS
Non-Executive Director
51,837 +1.2%
5.97
US$309,477 		51,837 +1.2% 5.97 US$309,477
2023-12-01 2023-11-29 B Purchase
3.5
Wedell-Wedellsborg Johan
Non-Executive Director
51,837 +1.2%
5.97
US$309,477 		51,837 +1.2% 5.97 US$309,477
2023-11-29 2023-11-28 B Purchase
3.5
Wedell-Wedellsborg Johan
Non-Executive Director
30,671 +0.7%
5.81
US$178,275 		30,671 +0.7% 5.81 US$178,275
2023-11-29 2023-11-28 B Purchase
3.8
WG Biotech ApS
Non-Executive Director
30,671 +0.7%
5.81
US$178,275 		30,671 +0.7% 5.81 US$178,275
2023-11-29 2023-11-27 B Purchase
3.5
Wedell-Wedellsborg Johan
Non-Executive Director
62,516 +1.5%
5.49
US$343,019 		62,516 +1.5% 5.49 US$343,019
2023-11-29 2023-11-27 B Purchase
3.8
WG Biotech ApS
Non-Executive Director
62,516 +1.5%
5.49
US$343,019 		62,516 +1.5% 5.49 US$343,019
2023-11-22 2023-11-21 S Sale
3.1
Gad Thomas

Chief Business Officer

Executive Director
75,000 -15.3%
5.31
US$397,988 		75,000 -15.3% 5.31 US$397,988
2023-11-22 2023-11-20 S Sale
3.1
Gad Thomas

Chief Business Officer

Executive Director
75,000 -13.3%
5.30
US$397,395 		75,000 -13.3% 5.30 US$397,395
2023-11-20 2023-11-20 PrS Proposed sale
3.1
Gad Enterprises LLC (Thomas Gad)

Officer

Officer
150,000
5.27
US$790,500 		150,000 5.27 US$790,500
2023-05-17 2023-05-15 B Purchase
3.5
Wedell-Wedellsborg Johan
Non-Executive Director
101,740 +2.4%
9.65
US$981,404 		101,740 +2.4% 9.65 US$981,404
2023-05-17 2023-05-15 B Purchase
3.8
WG Biotech ApS
Non-Executive Director
101,740 +2.4%
9.65
US$981,404 		101,740 +2.4% 9.65 US$981,404
2022-11-16 2022-11-15 B Purchase
1.9
Rajah Vignesh

SVP & CMO

Officer
1,195 +38.9%
4.92
US$5,884 		1,195 +38.9% 4.92 US$5,884
2022-02-23 2022-02-22 PlS Planned sale
1.5
Kruse Bo

EVP, CFO, Secretary & Treas.

Officer
4,000 -2.2%
7.85
US$31,400 		4,000 -2.2% 7.85 US$31,400
2022-02-09 2022-02-09 S Sale
3.1
Gad Thomas

See remarks

Executive Director
64,276 -10.2%
6.96
US$447,117 		64,276 -10.2% 6.96 US$447,117
2022-02-09 2022-02-08 S Sale
3.1
Gad Thomas

See remarks

Executive Director
125,863 -16.7%
7.01
US$882,891 		125,863 -16.7% 7.01 US$882,891
2022-02-09 2022-02-07 S Sale
3.1
Gad Thomas

See remarks

Executive Director
91,031 -10.8%
7.59
US$691,180 		91,031 -10.8% 7.59 US$691,180
2022-02-07 2022-02-04 PlS Planned sale
1.5
Kruse Bo

EVP, CFO, Secretary & Treas

Officer
4,000 -2.1%
7.97
US$31,880 		4,000 -2.1% 7.97 US$31,880
2022-02-07 2022-02-04 S Sale
3.1
Gad Thomas

See remarks

Executive Director
101,104 -10.7%
7.70
US$778,531 		101,104 -10.7% 7.70 US$778,531
2022-02-07 2022-02-03 S Sale
3.1
Gad Thomas

See remarks

Executive Director
35,060 -3.6%
7.90
US$277,027 		35,060 -3.6% 7.90 US$277,027
2022-02-03 2022-02-01 PlS Planned sale
3.1
Gad Thomas

See remarks

Executive Director
8,000 -13.8%
10.15
US$81,161 		8,000 -13.8% 10.15 US$81,161
2022-01-26 2022-01-24 S Sale
3.1
Gad Thomas

See remarks

Executive Director
55,783 -5.4%
10.96
US$611,281 		55,783 -5.4% 10.96 US$611,281
2022-01-26 2022-01-24 S Sale
3.1
Gad Thomas

See remarks

Executive Director
32,272 -3.0%
10.07
US$325,131 		32,272 -3.0% 10.07 US$325,131
2022-01-25 2022-01-24 PlS Planned sale
1.5
Kruse Bo

EVP, CFO, Secretary & Treas.

Officer
4,000 -2.1%
9.84
US$39,360 		4,000 -2.1% 9.84 US$39,360
2022-01-24 2022-01-21 S Sale
3.1
Gad Thomas

See remarks

Executive Director
20,184 -1.9%
11.35
US$229,103 		20,184 -1.9% 11.35 US$229,103
2022-01-24 2022-01-21 S Sale
3.1
Gad Thomas

See remarks

Executive Director
50,134 -4.4%
10.51
US$526,713 		50,134 -4.4% 10.51 US$526,713
2022-01-24 2022-01-20 S Sale
3.1
Gad Thomas

See remarks

Executive Director
112,767 -9.0%
11.33
US$1,277,289 		112,767 -9.0% 11.33 US$1,277,289
2022-01-20 2022-01-19 S Sale
3.1
Gad Thomas

See remarks

Executive Director
69,414 -5.2%
10.89
US$756,092 		69,414 -5.2% 10.89 US$756,092
2022-01-20 2022-01-18 S Sale
3.1
Gad Thomas

See remarks

Executive Director
400 -0.0%
11.46
US$4,584 		400 -0.0% 11.46 US$4,584
2022-01-20 2022-01-18 PlS Planned sale
3.1
Gad Thomas

See remarks

Executive Director
8,000 -13.8%
11.54
US$92,314 		8,000 -13.8% 11.54 US$92,314
2022-01-05 2022-01-04 PlS Planned sale
1.5
Kruse Bo

EVP, CFO, Secretary & Treas.

Officer
4,000 -2.0%
17.12
US$68,480 		4,000 -2.0% 17.12 US$68,480
2021-12-23 2021-12-22 PlS Planned sale
1.5
Kruse Bo

EVP, CFO, Secretary & Treas.

Officer
4,000 -2.0%
16.36
US$65,440 		4,000 -2.0% 16.36 US$65,440
2021-12-08 2021-12-07 S Sale
3.1
Gad Thomas

See remarks

Executive Director
10,000 -0.7%
17.58
US$175,832 		10,000 -0.7% 17.58 US$175,832
2021-12-08 2021-12-06 S Sale
3.1
Gad Thomas

See remarks

Executive Director
4,000 -0.3%
16.50
US$65,982 		4,000 -0.3% 16.50 US$65,982
Explore more

More insider trading research around Y-mAbs Therapeutics, Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America